Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence.

objectivesActivation of neutrophils and release of neutrophil extracellular traps (NETs), proteases and reactive oxygen species (ROS) is pathogenic in immune-mediated inflammatory diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), driving inflammation and damaging host tissues. The aim of this research was to identify small molecule inhibitors of NET production using a highly curated panel of narrow-spectrum small molecule kinase inhibitors termed the kinase chemogenomic set (KCGS).

methodsNeutrophils were isolated from healthy controls (HC) and people with RA or SLE. Over 220 small molecules were screened for their ability to inhibit NET production and decrease ROS production without impairing neutrophil apoptosis or killing of Staphylococcus aureus bacteria.

resultsFifty compounds, nominally targeting 29 individual protein kinases, were found to inhibit NADPH oxidase 2 (NOX2) -dependent (phorbol 12-myristate 13-acetate-stimulated) and NOX2-independent (A23187-stimulated) NET production (P < 0.05, n = 5 HC, RA and SLE). Of these, seven compounds did not significantly impair ROS production or apoptosis. The deconvoluted targets of these small molecules inhibit kinases that operate in three cellular pathways: autophagy, cell cycle checkpoint and epidermal growth factor tyrosine kinase signalling. Of these, only inhibitors of ULK1, JNK and ROCK1/2, broadly implicated in the regulation of autophagy, did not significantly impair bacterial killing (n = 5 HC, P > 0.05). Autophagy inhibitors were also able to inhibit immune-complex driven NET production (P < 0.05, n = 5 HC, RA and SLE).

conclusionWe propose that autophagy signalling pathways represent novel and exciting targets for the development of small molecule therapeutics to block unwanted neutrophil activation and NET release in immune-mediated inflammatory disease.